5 Key Takeaways

• 1

  Alcon's Voyager DSLT system enhances glaucoma treatment by providing a noncontact, automated approach that improves patient comfort and clinical workflow.

• 2

  DSLT effectively treats various types of glaucoma and ocular hypertension, expanding treatment eligibility for patients with difficult angles.

• 3

  Data from the LiGHT trial shows SLT, including DSLT, is superior to topical drops, resulting in less visual field loss and reduced need for surgeries.

• 4

  The GLAUrious study found that 62% of DSLT patients were medication-free after 12 months, demonstrating its efficacy compared to traditional SLT.

• 5

  Voyager DSLT's intuitive design and eye-tracking technology streamline treatment delivery, optimizing practice efficiency and enhancing patient experience.